Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600528094> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2600528094 abstract "1066 Background: Bevacizumab (BV), a monoclonal antibody directed against vascular endothelial growth factor (VEGF), is an approved anti-angiogenic agent, but despite its widespread use, little is known about how tumours develop resistance to BV. We have conducted a window-of-opportunity study in which BV is administered as a short-term first-line treatment for primary breast cancer (PBC) patients, and assessed histological markers of tumour angiogenesis and hypoxia before and after therapy. Methods: 47 patients with locally advanced breast cancer were prospectively enrolled. Informed consent was obtained from all patients. A single infusion of BV (15 mg/kg) was given 2 weeks before starting neoadjuvant chemotherapy. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and core biopsies for immunohistochemistry (IHC) analysis were performed immediately prior to and 2 weeks after BV. 36 patients with invasive ductal carcinoma and good quality MRI scans and core biopsies were included in this analysis. Wilcoxon rank test and Spearman’s correlation test were used for statistical analysis. Results: IHC revealed a significant upregulation of carbonic anhydrase 9 (P = 0.04) and hypoxia inducible factor-1a (P = 0.001) following BV therapy along with a significant reduction in plasmalemma vesicle associated protein (PLVAP) (p=0.01) and Ki67 (p= 0.006). DCE-MRI analysis revealed a significant reduction in vessel permeability and blood flow following BV, as measured by a decrease in the forward transfer constant K trans (P < 0.0001) and the reverse rate constant k ep (P < 0.0001). In addition, we found a significant negative correlation between CA9 levels and median K trans at baseline (Spearman’s rho = -0.46; P = 0.01). Conclusions: Using combined DCE-MRI and IHC analysis, we found that PBC patients treated with single-agent BV showed a decrease in markers of tumour angiogenesis, together with a corresponding increase in tumour hypoxia. Our results suggest that tumour hypoxia may be a key mechanism governing the early onset of resistance to BV therapy, and argue for the use of suitable combination therapies to overcome the resistance and ultimately improve patient survival." @default.
- W2600528094 created "2017-04-07" @default.
- W2600528094 creator A5016309859 @default.
- W2600528094 creator A5018411240 @default.
- W2600528094 creator A5032003471 @default.
- W2600528094 creator A5032961407 @default.
- W2600528094 creator A5033223978 @default.
- W2600528094 creator A5035568586 @default.
- W2600528094 creator A5038797638 @default.
- W2600528094 creator A5065843522 @default.
- W2600528094 creator A5067644744 @default.
- W2600528094 creator A5075828750 @default.
- W2600528094 creator A5089204546 @default.
- W2600528094 date "2012-05-20" @default.
- W2600528094 modified "2023-09-23" @default.
- W2600528094 title "Early changes in angiogenesis and hypoxia following bevacizumab therapy in primary breast cancer." @default.
- W2600528094 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.1066" @default.
- W2600528094 hasPublicationYear "2012" @default.
- W2600528094 type Work @default.
- W2600528094 sameAs 2600528094 @default.
- W2600528094 citedByCount "0" @default.
- W2600528094 crossrefType "journal-article" @default.
- W2600528094 hasAuthorship W2600528094A5016309859 @default.
- W2600528094 hasAuthorship W2600528094A5018411240 @default.
- W2600528094 hasAuthorship W2600528094A5032003471 @default.
- W2600528094 hasAuthorship W2600528094A5032961407 @default.
- W2600528094 hasAuthorship W2600528094A5033223978 @default.
- W2600528094 hasAuthorship W2600528094A5035568586 @default.
- W2600528094 hasAuthorship W2600528094A5038797638 @default.
- W2600528094 hasAuthorship W2600528094A5065843522 @default.
- W2600528094 hasAuthorship W2600528094A5067644744 @default.
- W2600528094 hasAuthorship W2600528094A5075828750 @default.
- W2600528094 hasAuthorship W2600528094A5089204546 @default.
- W2600528094 hasConcept C121608353 @default.
- W2600528094 hasConcept C126322002 @default.
- W2600528094 hasConcept C143998085 @default.
- W2600528094 hasConcept C178790620 @default.
- W2600528094 hasConcept C185592680 @default.
- W2600528094 hasConcept C2776694085 @default.
- W2600528094 hasConcept C2777802072 @default.
- W2600528094 hasConcept C2780394083 @default.
- W2600528094 hasConcept C2992356464 @default.
- W2600528094 hasConcept C31194975 @default.
- W2600528094 hasConcept C530470458 @default.
- W2600528094 hasConcept C540031477 @default.
- W2600528094 hasConcept C71924100 @default.
- W2600528094 hasConcept C7836513 @default.
- W2600528094 hasConceptScore W2600528094C121608353 @default.
- W2600528094 hasConceptScore W2600528094C126322002 @default.
- W2600528094 hasConceptScore W2600528094C143998085 @default.
- W2600528094 hasConceptScore W2600528094C178790620 @default.
- W2600528094 hasConceptScore W2600528094C185592680 @default.
- W2600528094 hasConceptScore W2600528094C2776694085 @default.
- W2600528094 hasConceptScore W2600528094C2777802072 @default.
- W2600528094 hasConceptScore W2600528094C2780394083 @default.
- W2600528094 hasConceptScore W2600528094C2992356464 @default.
- W2600528094 hasConceptScore W2600528094C31194975 @default.
- W2600528094 hasConceptScore W2600528094C530470458 @default.
- W2600528094 hasConceptScore W2600528094C540031477 @default.
- W2600528094 hasConceptScore W2600528094C71924100 @default.
- W2600528094 hasConceptScore W2600528094C7836513 @default.
- W2600528094 hasLocation W26005280941 @default.
- W2600528094 hasOpenAccess W2600528094 @default.
- W2600528094 hasPrimaryLocation W26005280941 @default.
- W2600528094 hasRelatedWork W1972865531 @default.
- W2600528094 hasRelatedWork W1973283880 @default.
- W2600528094 hasRelatedWork W1974095540 @default.
- W2600528094 hasRelatedWork W1980411249 @default.
- W2600528094 hasRelatedWork W1987039497 @default.
- W2600528094 hasRelatedWork W2018437141 @default.
- W2600528094 hasRelatedWork W2022859640 @default.
- W2600528094 hasRelatedWork W2039548371 @default.
- W2600528094 hasRelatedWork W2070119976 @default.
- W2600528094 hasRelatedWork W2075448429 @default.
- W2600528094 hasRelatedWork W2108814039 @default.
- W2600528094 hasRelatedWork W2181158647 @default.
- W2600528094 hasRelatedWork W2209471899 @default.
- W2600528094 hasRelatedWork W2244920636 @default.
- W2600528094 hasRelatedWork W2246286923 @default.
- W2600528094 hasRelatedWork W2404168435 @default.
- W2600528094 hasRelatedWork W2795103935 @default.
- W2600528094 hasRelatedWork W47853191 @default.
- W2600528094 hasRelatedWork W1931046715 @default.
- W2600528094 hasRelatedWork W2265944765 @default.
- W2600528094 isParatext "false" @default.
- W2600528094 isRetracted "false" @default.
- W2600528094 magId "2600528094" @default.
- W2600528094 workType "article" @default.